- Home
- MTR vs IMNN Comparison
MTR vs IMNN Comparison
Compare MTR & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MTR | IMNN |
|---|---|---|
| Founded | 1979 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7M | 11.5M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | MTR | IMNN |
|---|---|---|
| Price | $4.81 | $3.10 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 9.2K | ★ 69.3K |
| Earning Date | 03-31-2026 | 05-11-2026 |
| Dividend Yield | ★ 4.81% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $22.60 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.03 | $0.37 |
| 52 Week High | $10.42 | $9.32 |
Technical Indicators
Market Signals| Indicator | MTR | IMNN |
|---|---|---|
| Relative Strength Index (RSI) | 46.30 | 51.98 |
| Support Level | $4.57 | $3.00 |
| Resistance Level | $4.89 | $3.24 |
| Average True Range (ATR) | 0.16 | 0.19 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 43.75 | 74.19 |
Price Performance
Historical ComparisonAbout MTR Mesa Royalty Trust
Mesa Royalty Trust holds net overriding royalty interests in various oil and gas properties located in the: Hugoton field of Kansas, San Juan Basin field of New Mexico, and San Juan Basin Field of Colorado.
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit an immunological response. The company's clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer.